在患有复杂心力衰竭的患者中协作管理高卡血症
Ellie Kelepouris1, Nihar Desai2, Katherine A A Clark2
1Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Case reports in nephrology and dialysis
|April 16, 2025
概括
综合护理团队可以在心力衰竭 (HF) 和脏疾病患者中管理高卡莱米亚,优化氨酸-氨酸-阿尔多斯特系统抑制剂 (RAASi) 治疗. 这种方法通过避免RAASi剂量减少和随后的HF症状复发来改善结果.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 和脏疾病经常同时存在.
- 超血是常见的并发症,经常需要降低氨酸- ангиотензин- 阿尔多素系统抑制剂 (RAASi) 的剂量.
- RAASi治疗对于HF管理至关重要,但存在高胆固醇血的风险.
研究的目的:
- 提出一个框架,用于综合多专业团队管理HF和病患者的高胆血症.
- 突出协作护理在优化医疗治疗中的好处.
- 通过有效的高血症管理来改善临床结果.
主要方法:
- 在RAASi升位后,提出了急性HF脱补偿与高胆血症的假设病例.
- 两种管理场景进行了比较:典型的RAASi降级与协作跨学科管理.
- 合作方法涉及密切监测,饮食变化和结合剂治疗.
主要成果:
- 降低RAASi的标位以预防高血症导致HF症状复发和重新住院.
- 协作跨学科的方法允许保持指南导向的RAASi剂量.
- 这一策略有效地管理了高胆血症,同时保持了RAASi治疗的好处.
结论:
- 多专业团队的协作可以在不停止RAASi治疗的情况下成功管理HF患者的高胆血症.
- 综合性心脏病诊所可以促进讨论和制定复杂病例的当地指导方针.
- 这种协作模式优化了患者护理和临床结果.
相关概念视频
01:22Heart Failure Drugs: Diuretics
294
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
294
01:26Heart Failure Drugs: Inotropic Agents
424
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
424
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
321
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
407
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
407
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:22Heart Failure Drugs: β-Blockers
278
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
278